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ABSTRACT
High-grade epithelial ovarian cancer (HGEOC) is a clinically diverse and 
molecularly heterogeneous disease comprising subtypes with distinct biological 
features and outcomes. The receptor tyrosine kinases, expressed by EOC cells, and 
their ligands, present in the microenvironment, activate signaling pathways, which 
promote EOC cells dissemination. Herein, we established a molecular link between 
the presence of Gas6 ligand in the ascites of HGEOCs, the expression and activation 
of its receptor Axl in ovarian cancer cell lines and biopsies, and the progression of 
these tumors. We demonstrated that Gas6/Axl signalling converges on the integrin 
β3 pathway in the presence of the adaptor protein p130Cas, thus inducing tumor 
cell adhesion to the extracellular matrix and invasion. Accordingly, Axl and p130Cas 
were significantly co-expressed in HGEOC samples. Clinically, we identified an Axl-
associated signature of 62 genes able to portray the HGEOCs with the shortest overall 
survival. These data biologically characterize a group of HGEOCs and could help guide 
a more effective therapeutic approach to be taken for these patients.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth leading 
cause of cancer-related deaths among women and of death 
among all gynecologic tumors [1]. In spite of progress in 
its diagnosis and treatment, EOC incidence and mortality 
rates have been mostly unchanged over the last 30 years 
[2]. The most recent EOC classification identifies 
genetically stable, low-grade type I tumors, and high-
grade (HGEOC) type II tumors, characterized by a high 
chromosomal instability and intra-tumor heterogeneity 
[3]. HGEOC, fallopian tubal, and peritoneal carcinomas 
are considered a single clinical entity due to their shared 
clinical behavior and treatment; however, HGEOC is a 
morphological and molecularly heterogeneous disease, 
and a rational approach for optimal therapeutic regimens 
has not yet been provided. In the most recent years, gene 
expression profiles have been widely exploited to better 
characterize the biology of these tumors and to generate 
a patient classification aimed at identifying the most 
efficacious therapeutic approach to take [4–8].
HGEOCs rarely metastasize to distant sites, but 
instead disseminate over the surface of the peritoneum [9]. 
The dissemination process occurs when a single tumor cell 
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or small clusters are shed from the primary site or from 
peritoneal secondary lesions. These floating multicellular 
cancer aggregates (MCAs) overcome anoikis, persist 
in ascites, and then re-adhere on the surface of the 
peritoneum or omentum, suggesting that the attachment 
of cancer cells to the basement membrane is a key step in 
HGEOC dissemination.
These processes require the contribution of cell 
adhesion molecules and receptor tyrosine kinases (RTKs), 
expressed by EOC cells, and their ligands, present in the 
tumor microenviroment. Among RTKs, Axl, belonging 
to the TAM RTK family together with Mer and Tyro3, is 
frequently overexpressed in several human solid tumors, 
and can influence tumorigenicity, invasiveness, metastasis 
formation, or resistance to therapeutic agents [10]. 
Treatment with a soluble Axl moiety, which is able to inhibit 
the binding of one of its ligands, Gas6, to the membrane-
bound Axl, has been shown to reduce the peritoneal 
metastatic EOC burden in mice [11]. Accordingly, Axl 
knockdown in ovarian cancer SKOV3 cells has been shown 
to reduce PI3K/Akt activation and the expression of MMP-
1 and MMP-9, both in vitro and in vivo using the peritoneal 
xenograft model of ovarian cancer [11].
The natural ligand of Axl is the 75 kDa vitamin 
K-dependent protein Gas6 [12]. Gas6 is physiologically 
involved in a wide range of cellular responses, including cell 
survival, angiogenesis, phagocytosis, platelet aggregation, 
vascular biology, inflammation, and immunity [12]. Soluble 
Gas6 is also present in plasma at a concentration of around 
20–50 ng/mL (0.25 nmol/L) [13]. In solid tumors, Gas6 
promotes the proliferation of prostate cancer cells [14].
The oncogenic nature of Axl is demonstrated 
through its activation of the signaling pathways involved 
in the proliferation, migration, and inhibition of apoptosis, 
and in therapeutic resistance [15]. In melanomas, Axl gene 
expression is associated with the most invasive tumors and 
with resistance to BRAF inhibitors [16, 17]. The presence 
of Gas6 in the human HGEOC microenvironment, the 
molecular processes activated downstream of Gas6-
stimulated HGEOC cells, and the impact of this signaling 
cascade on HGEOC patients’ outcomes have not been so 
far assessed. Therefore, herein, we aimed to investigate the 
signaling cascade activated by the Gas6/Axl axis and to 
evaluate the clinical relevance of Axl expression.
RESULTS
Gas6 is expressed in EOC cells and activates the 
TAM RTK Axl
We first checked by real time RT-PCR the 
expression of Gas6 and Axl, Mer, and Tyro-3 in a panel of 
human ovarian cancer cell lines. OVCAR4 and SKOV3 
cells expressed the highest levels of Gas6 (Fig. 1A), 
while OVCAR5 and NL3507 barely showed detectable 
Gas6 transcript. The expression of TAM receptors was 
heterogeneous, Axl being expressed at high levels in 
OVCAR5, NL3507, and SKOV3 cells, in both the RT-PCR 
and western blotting experiments (Fig. 1A and 1B). Mer 
and Tyro-3 were expressed at low levels in all cell lines 
(Fig. 1A and 1B); slightly higher levels of Mer were 
observed in IGROV1, OVCAR5, OAW42, and NL3507, 
while Tyro3 expression was found to be higher in 
OVCAR5 and SKOV3.
To assess which TAM receptors were activated by 
Gas6 stimulation, immunoprecipitation (IP) with an anti-
phosphotyrosine (p-Tyr) antibody (Ab) was performed 
on starved SKOV3 cells (expressing Axl and Tyro-3), 
and on starved NL3507 cells (expressing Axl and Mer), 
with and without stimulation with Gas6 (500 ng/ml). In 
both cell lines, Axl was basally slightly phosphorylated, 
probably by endogenously produced Gas6 (see Fig. 1A), 
while Gas6 stimulation induced increased levels of Axl 
phosphorylation (Fig. 1C). In SKOV3 cells, a slight 
amount of phosphorylated Tyro-3 was observed, while in 
NL3507 Mer and Tyro-3 were not phosphorylated upon 
Gas6 stimulation (Fig. 1C). None of the TAM receptors 
was immunoprecipitated with a mouse anti-serum 
(Supplementary Fig. 1). In both Gas6-stimulated cell lines, 
phosphorylation of Axl was inhibited by the presence of 
the recombinant Axl-Fc protein (Fig. 1D).
These data demonstrate that the Gas6 stimulation of 
ovarian cancer cells activates RTK Axl.
Gas6-stimulated promotion of invasion through 
the interaction between ovarian cancer cells  
and ECM
Next, we assessed whether Gas6 stimulation 
induced ovarian cancer cell invasion. We cultured SKOV3 
and NL3507 cells in reduced growth factor Matrigel-
embedded 3D to drive the formation of spheroids, in 
order to mimic the invasion process occurring in vivo. 
After 5 days, single cells from both cell lines were able 
to form spheroids in Matrigel (Fig. 2A, left panels). The 
spheroids were serum-starved and were tested stimulated 
and unstimulated with Gas6 to evaluate its effect on 
cell behavior. Gas6 stimulation induced the formation 
of a stellate invasive phenotype characterized by 
invadopodia and chains of cells invading the surrounding 
Matrigel, reminiscent of a collective cell invasion 
(Fig. 2A, right panel). To test whether the interaction 
with a component of the ECM was essential for Gas6-
induced invasion, we used an inert 3D alginate scaffold, 
the AlgiMatrix™, with which human integrins do not 
interact [18]. SKOV3 spheroids, grown in AlgiMatrix™ 
for 12 days, were serum starved and stimulated or not 
with Gas6. In contrast to what we observed before, 
in the absence of Matrigel, Gas6 did not induce any 
SKOV3 spheroids morphological changes (Fig. 2B, left 
panel). AlgiMatrix™-cultured SKOV3 spheroids were 
then embedded in Matrigel (as described in the scheme 
displayed in Supplementary Fig. 2), and stimulated or not 
with Gas6, as above. As observed in panel A, an invasive 
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morphology was observed only in the presence of Gas6 
(Fig. 2B, right panel).
These results indicate that Gas6 stimulation 
alone is not sufficient to induce changes in SKOV3 
cell morphology but the interaction of Gas6-stimulated 
cells with ECM induces cellular changes. To assess 
the contribution of ECM proteins to Axl activation by 
Gas6, starved SKOV3 and NL3507 cells were allowed 
to adhere for 30 min on plastic or fibronectin (FN)-
coated dishes, in the presence or absence of Gas6. Axl 
activation was assessed in total cell lysates by western 
blotting. The Gas6 stimulation of FN adherent cells 
induced about two fold Axl phosphorylation levels in 
respect to the plastic adherent cells (Fig. 2C). Since Axl 
phosphorylation should trigger PI3K/AKT activation 
[11], we also observed a higher AKT phosphorylation 
upon Gas6 stimulation. Both FN adherent SKOV3 
and NL3507 cells showed AKT phosphorylation 
significantly higher with respect to the cells grown on 
plastic (Fig. 2C, lower panel). Among the different 
integrin β chain molecules, SKOV3 and NL3507 cells 
express β3, as assessed by FACS analysis (Fig. 2D, 
upper panel, and Supplementay Fig. 3). To assess 
whether β3 integrin was involved in Gas6-stimulated 
Axl activation, NL3507 cells were allowed to adhere on 
FN-coated dishes for 30 min in the presence of Ab able 
to inhibit integrin β3/FN interaction. As expected, by 
preventing the binding of integrin β3 to the ECM, Gas6-
induced Axl tyrosine phosphorylation was completely 
eliminated (Fig. 2D, lower panel).
These data clearly show, for the first time, that the 
Gas6-stimulated Axl signaling pathway is dependent on 
the adhesion of ovarian cancer cells to the ECM through 
the integrin β3.
Gas6/Axl signaling triggers PI3K/AKT/rac 
activation and requires the scaffold protein 
p130Cas
In order to assess the biochemical and cellular 
mechanisms activated in ovarian cancer cells by Gas6, 
SKOV3 cells were Gas6 stimulated while adhering 
to FN, and the actin assembly was evaluated by 
immunofluorescence (IF) with labeled phalloidin. Gas6-
induced protrusive structures at the leading edge were 
associated with the presence of stress fibers (Fig. 3A). 
Figure 1: Gas6 is expressed in EOC cells and activates the TAM RTK Axl. A. Real-time PCR showing the levels of mRNA for 
Gas6, AXL, MERTK, and TYRO-3 in six EOC cell lines. Results are presented as relative expression normalized to GAPDH mRNA levels. 
B. Western blotting on the total cell lysates from the same six EOC cell lines. C. IP with Anti-P-Tyrosine (P-Tyr) performed on lysates from 
starved or Gas6-stimulated SKOV3 and NL3507 cells. Immunoprecipitated samples were analyzed by western blotting with Abs against 
the proteins reported on the right. D. Western blotting on the total cell lysates from starved SKOV3 and NL3507 cells pre-treated with 
Axl-Fc (2.5 μg/ml) and stimulated or not with Gas6 (500 ng/ml). Abs are reported on the right. β-actin was used as the gel loading control.
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Figure 2: Gas6-stimulated promotion of invasion through the interaction between ovarian cancer cells and 
ECM. A. Invasion assay of starved or Gas6-stimulated SKOV3 and NL3507 cells grown in Matrigel. Representative images of three 
independent experiments are shown. B. Left panel, phase contrast microscopy of starved or Gas6-stimulated SKOV3 cells grown and 
stimulated with Gas6. C. Upper panel, western blotting on the total cell lysates from starved or Gas6-stimulated SKOV3 and NL3507 cells 
seeded on FN for 30 min. A representative experiment of the three performed is shown. Abs are reported on the right. β-actin was used as the 
gel loading control. Lower panel, quantitative evaluation of phosphorylated Axl in Gas6-stimulated cells upon adhesion on FN. The graph 
reports the mean ± SD from the three independent experiments. D. Upper panel, membrane staining of the integrin β3 receptor determined 
by flow cytometry on the NL3507 cell line. The expression of the other integrin β receptors on both the SKOV3 and NL3505 cells was 
also evaluated and the results are reported in Supplementary Fig. 3. The red and light blue peaks, respectively, represent the fluorescence 
of the cells incubated with the secondary antibody alone as control (α-mouse) and the anti-integrin β3 Ab (Anti-β3). Lower panel, western 
blotting on the total cell lysates from starved or Gas6-stimulated NL3507 cells, in the absence or in the presence of the anti-integrin β3 Ab. 
A representative experiment is shown. Abs are reported on the right. β-actin was used as the gel loading control.
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In the presence of R428, an inhibitor of Axl 
phosphorylation, actin nucleation was inhibited, as well as 
the formation of stress fibers. Interestingly, the treatment 
of FN-adherent SKOV3 cells with the rac inhibitor 
EHT1864 recapitulated the effect of the Axl inhibitor on 
actin assembly and the formation of stress fibers.
These results were further supported by inhibition 
of the invasion of Gas6-stimulated SKOV3 spheroids in 
Matrigel by both the Axl and rac inhibitors (Fig. 3B). 
Furthermore, the treatment of SKOV3 cells with the 
src inhibitor PP2 did not inhibit Gas6-induced Matrigel 
invasion (data not shown).
The synergism between RTKs and integrins is 
mediated by intracellular scaffold proteins, such as FAK 
and p130Cas, which integrate both signalings leading to 
the intracellular response [19]. To study if these scaffold 
proteins could be the mediator(s) between Gas6/Axl and 
ECM, the possible interaction between Axl and p130Cas 
or FAK was analyzed by IP, as performed on starved 
SKOV3 stimulated or not with Gas6. Total cell lysates 
were immunoprecipitated with anti-p130Cas (Fig. 3C, 
upper panel) or-FAK Abs (lower panel) and the obtained 
protein complexes were analyzed by western blotting with 
anti-Axl Ab. Axl co-immunoprecipitated with the p130Cas 
Figure 3: Gas6/Axl signaling triggers PI3K/AKT/rac activation and requires the scaffold protein p130Cas. A. IF 
performed on SKOV3 cells grown on FN, starved and then induced to migrate through a wound in the presence or not of Gas6. Cells 
were treated with the reported inhibitors, and F-actin was stained with phalloidin (red). B. Invasion assay of starved or Gas6-stimulated 
SKOV3 and NL3507 cells grown in Matrigel. Cells were treated with the reported inhibitors. Representative images of the three 
independent experiments are shown. C. IP performed with anti-p130Cas (upper panel) or with anti-FAK (lower panel), respectively, on 
lysates of starved or Gas6-stimulated SKOV3 cells. Normal mouse or rabbit (IgG) sera were used as the negative control, respectively. The 
immunoprecipitated samples were analyzed by western blotting. D. Western blotting on the total cell lysates from SKOV3 cells transiently 
transfected with a control siRNA (-) or with a pool of siRNA against p130Cas (sip130Cas). SiRNA-transfected SKOV3 cells were starved 
or Gas6-stimulated and seeded on FN for 30 min. Immunoblottings were performed with Abs against the proteins reported on the right. 
Alpha (tubulin) was used as the gel loading control.
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scaffold protein in the absence and in the presence of Gas6 
(Fig. 3C, upper panel), while it only slightly interacted 
with FAK (lower panel).
To test whether p130Cas was essential for Gas6/Axl 
signaling activation, p130Cas was transiently silenced 
in SKOV3 cells. The cells were then serum starved, and 
stimulated or not with Gas6 during adhesion on FN. The 
p130Cas-silenced SKOV3 cells, adherent on plastic or 
on FN, showed a decreased level of phosphorylated Axl 
compared to the control-silenced cells (Fig. 3D). As 
expected, both unstimulated and Gas6-stimulated FN 
adherent cells showed higher levels of Axl phosphorylation 
with respect to the cells adherent on plastic.
Altogether, these data suggest that Gas6/Axl 
signaling leads to PI3K/AKT/rac activation in ECM-
adherent ovarian cancer cells in a src-independent way. 
Furthermore, p130Cas is necessary for maximum Gas6-
stimulated Axl activation.
Reduction of Gas6-dependent adhesion and 
invasion following the impairment of p130Cas/
Axl interactions
To further clarify the role of p130Cas in the Gas6-
dependent Axl activation and its contribution to ovarian 
cancer cell interaction with the ECM, SKOV3 cells were 
transiently transfected with siRNA targeting p130Cas or 
with a control siRNA. Silenced cells were then starved, 
and, while plated on FN, cell adhesion was monitored 
for up to 1 h by live imaging in the presence or absence 
of Gas6. Both the control and p130Cas-silenced SKOV3 
cells did not adhere in the first 10 min and required 20 
min to adhere to FN (Fig. 4A and 4B, and Supplementary 
Video 1). Upon Gas6 stimulation, the control-silenced 
cells started to adhere to FN after 5 min, and after 20 min 
were completely spread on the substrate (Fig. 4A and 4B 
and Supplementary Video 1 and 2), while a lower number 
of Gas6-stimulated p130Cas-silenced cells adhered on FN 
after 20 min (Fig. 4B) since the adhesion was impaired. 
Indeed, p130Cas-silenced cells, under Gas6 stimulation, 
formed an adhesion structure similar to membrane blebs 
emerging on the cell surface, but they were not able to 
complete the adhesion process (Supplementary Video 2).
To investigate the role of p130Cas in Gas6-
dependent filopodia formation, actin cytoskeleton analysis 
was performed on control- and p130Cas-silenced SKOV3 
cells plated on FN and stimulated with Gas6 (Fig. 4C). 
Upon Gas6 stimulation, control-silenced cells plated on 
FN showed the formation of a filopodia-like structure, as 
already observed in Fig. 3A, while p130Cas-silenced cells 
appeared rounded with bleb-like structures (as observed in 
the phase contrast microscopy image of Fig. 4A) and not 
attached to the substrate (Fig. 4C).
We next aimed to clarify whether p130Cas was also 
essential in the Gas6-dependent invasion. For this aim, an 
invasion assay was performed with SKOV3 cells stably 
silenced for p130Cas, using a shRNA-containing lentiviral 
vector, in order to follow the experiment for the required 
time. The infected Mock- and shp130Cas-SKOV3 cells, 
respectively, were embedded in reduced growth factor 
Matrigel and the obtained spheroids were then stimulated 
or not with Gas6. Upon Gas6 stimulation, the shp130Cas-
SKOV3 cells maintained a perfect spherical shape 
(Fig. 4D), while the Mock-SKOV3 spheroids formed 
structures that invade into the surrounding Matrigel 
(Fig. 4D).
These data strongly indicate that Gas6-dependent 
adhesion mediated by integrin signaling/p130Cas is 
essential for adhesion to ECM and for invasion.
Validation on ascites, patient-derived tumor 
cells, and on the biopsies of HGEOCs
To clinically validate the results obtained in vitro 
in established ovarian cancer cell lines, we first assessed 
the presence of Gas6 in 22 HGEOC ascites, whose 
characteristics have been described elsewhere [20]. We 
found that the levels of Gas6 ranged from 43 to 103 ng/
ml, with a mean value of 74.1 ng/ml, and were statistically 
higher than the Gas6 levels in 22 ascites from non-
malignant pathologies (Fig. 5A). To evaluate the possible 
sequestration of Gas6 by the Axl ectodomain present in 
the EOC ascites, the levels of this form of soluble Axl 
ectodomain was also measured. As shown in Fig. 5B, the 
Axl molecules were not able to completely sequester the 
Gas6 molecules in 20 out of the 22 ascites,  indicating that 
Gas6 was available for the stimulation of Axl receptors 
expressed by HGEOC cells.
To test if Gas6 stimulation could exert the same 
effect on ovarian cancer cells obtained from malignant 
ascites, two samples from patients with serous HGEOC 
were allowed to adhere on Matrigel in the presence or 
in absence of Gas6 and the cancer cells invasion was 
monitored by phase contrast microscopy. In accord with 
what is observed for ovarian cancer cell lines, in HGEOC 
patient-derived spheroids, Gas6 induced a stellate invasive 
phenotype (Fig. 5C). IP with anti-Axl Ab performed on 
the total cell lysates obtained from the serous HGEOC of 
patient #1 demonstrated the association between Axl and 
p130Cas also in vivo (Fig. 5D).
In addition, the expression of Axl and p130Cas 
was analyzed by immunohistochemistry (IHC) on 
archival case material, which showed that, among 
72 EOC primary tumors, the majority express Axl at the 
cell membrane (80%) (Supplementary Table 1). Eighty 
percent of the same EOC samples also co-expressed 
p130Cas in the cytoplasm (representative samples in 
Fig. 5E), and, moreover, Axl and p130Cas co-expression 
could distinguish between type I and type II (HGEOCs) 
as evaluated by Fisher’s Exact Test (p = 0,0009, Fig. 5F).
These data, together with the biochemical and 
cellular results obtained in vitro, strongly support the 
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idea that, in HGEOCs, the Gas6/Axl signaling cascade is 
activated in p130Cas-expressing cells.
Identification of an Axl–driven signature in 
serous HGEOCs
We then analyzed Axl-expressing HGEOCs in 
order to assess their biological characteristics. Pearson’s 
correlation analysis was performed to identify genes 
whose expression was significantly correlated with 
Axl expression in three data sets [4, 8, 21]. These data 
sets, reporting the gene expression profiles of a total of 
976 HGEOC patients (Supplementary Table 2), allowed 
us to identify distinct HGEOC subtypes displaying 
different biological features with statistical prognostic 
relevance. Probes were filtered for an AXL-correlation 
higher than 0.4 and a p value lower than 0.05, and unique 
gene symbols were considered for further analysis. 
A comparison performed across the three data sets pointed 
out 121 concordantly correlated genes including Axl, 
(see the Venn diagram of Supplementary Fig. 4, Table 1 
and Supplementary Table 3). These genes were enriched 
for those encoding ECM components (like collagens, 
FBN, FN, DCN) or adhesion molecules (like CDH11, 
and different integrin components); for those encoding 
matrix metalloproteases (MMP2 and 19, TIMP3), for 
epithelial-mesenchymal-transcription (EMT)-associated 
transcription factors (ZEB1, ZEB2); and for TGBB1, a 
classical EMT regulator. On the other hand, no significant 
correlation was found between Axl and the companion 
Figure 4: Reduction of Gas6-dependent adhesion and invasion following the impairment of p130Cas/Axl 
interactions. A. Live cell imaging performed on untreated (-) or Gas6-stimulated control siRNA (siCO)- or p130 siRNA (sip130Cas)-
transfected SKOV3 cells during adhesion on FN (see Supplementary Video 1 and 2, and Methods). Representative frames at 0, 10 min, and 
20 min are reported. Scale bar, 100 μm. B. Graph reporting the number of FN adherent siCo- or sip130Cas-transfected SKOV3 cells, from 
the live imaging experiment, taken at different time points. Asteriscs indicate the significant differences between the two curves (paired 
t test, p = 0.0004) C. IF performed on cells as above after 20 min of adhesion on FN. The F-actin was stained with phalloidin (green). 
D. Invasion assay performed in Matrigel on starved or Gas6-stimulated SKOV3 cells stably p130Cas-silenced (shp130Cas) or infected 
with an empty shRNA vector (Mock). Representative images of the three independent experiments are shown.
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Figure 5: In vivo validation on HGEOC samples. A. Gas6 levels measured by ELISA on 22 EOC ascites and 22 non-malignant 
ascites. B. Evaluation in the EOC ascites of the sequestration by the Axl ectodomain of Gas6. The dosage of the two molecules was 
performed as described in Methods. The graph reports the molar ratio between Gas6 and Axl ectodomain (sAxl). The red line represents 
the equimolar ratio. C. Invasion assay performed on starved or Gas6-stimulated MCAs from two representative Axl-positive MCAs from 
EOC ascites grown in Matrigel. EOC samples containing 80% of HGEOC cells, as evaluated by the cytopathologist, were processed. 
Satellite cells present in the starved sample are likely to be some immune cells present in the sample D. IP performed on the total cell lysates 
obtained from the EOC cells of patient #1 with anti-p130Cas. Immunoprecipitated samples were analyzed by western blotting with Abs 
against the proteins reported on the right. A longer exposure of the immunoblot with both Abs on the total lysates is shown on the right. 
E. Representative staining with anti-Axl and anti-p130Cas Abs on FFPE sections from two (a and b) HGEOC patients . Scale bar, 50 μm. 
F. Graph reporting the correlation between the p130Cas and Axl expressions in Type I and Type II (HGEOCs) tumors. The results of the 
contingency analysis are reported (Fisher’s exact test, p = 0,0009).
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receptors, or its ligand Gas6 or the gene encoding p130Cas 
(BCAR1).
To validate these data on clinical HGEOC samples, 
real-time RT-PCR was performed on RNA extracted from 
eight serous HGEOCs (Supplementary Table 4) for eight 
genes (CDH11, CXCL12, DCN, FN1, MMP2, PLAU, 
TGFB1, ZEB2) included in the identified 121-gene set . 
Among these genes, the expression of four of them (DCN, 
FN1, MMP2, and PLAU) was significantly correlated 
to AXL expression (R2 range: 0.76–0.86; p value range: 
0.0048–0.00012), while that of CDH11 showed an 
R2 = 0.48 but a borderline significance (p = 0.057), and 
the expression of three of them (CXCL12, TGFB1, and 
ZEB2) was not correlated to AXL (Supplementary Fig. 5).
To provide an insight into the possible biological 
significance of the 121-gene set, a functional analysis 
of the correlated genes was carried out by Ingenuity 
Pathway Analysis software (IPA) [22]. Among the five top 
Molecular and Cellular Functions, ‘Cellular movement’ 
and ‘Cellular morphology’ were included (Supplementary 
Table 5A). Two of the five networks associated with the 
highest score, named N1 and N2, were ‘Connective Tissue 
Disorders, Dermatological Diseases and Conditions, 
Developmental Disorder’ and ‘Cancer, Organismal 
Injury and Abnormalities, Reproductive System Disease’ 
(Supplementary Fig. 6). N1 contained several ECM 
proteins (different types of collagen, CDH11, DCN), 
together with the integrin αvβ3 receptor genes, and AKT 
as the hub gene. N2 included genes associated to cell 
morphology and to the actin cytoskeleton (Supplementary 
Table 5B). These data, obtained on a large number of 
HGEOC patients, are concordant with the in vitro data 
of Gas6/Axl-induced AKT activation and of a crosstalk 
between the Axl and ECM/integrin signaling pathways.
To investigate whether the Axl-associated gene set 
could impact on a specific HGEOC subtype, the change 
in expression of each gene of our gene set was evaluated 
for each subtype identified in data set II [5]. The entire 
Axl-associated gene set increased in the ‘mesenchymal’ 
subtype while it was decreased in the ‘proliferative’ 
subtype and in the ‘differentiated’ subtype (Fig. 6A), 
strongly suggesting that the tumors from these subtypes 
display different altered signaling pathways. On the 
other hand, the ‘immunoreactive’ subtype presented 
both increased and decreased genes (Fig. 6A). In the 
‘immunoreactive’ subtype, the increase of Axl was 
lower than in the mesenchymal subtype (gene rank F 
score = 1.6 vs 8.6, as evaluated by Verhaak et al. [5]). 
This was likely due to the presence of a large number of 
immune cells in these samples, as also stated by the same 
authors [5]. Hence, to select for Axl-correlated genes 
likely altered only in HGEOC cells, all genes showing 
an F score ≤ 1.6 were excluded from the Axl-associated 
gene set (see the Methods section), thus generating an 
Table 1: Biological identification of the Axl-associated gene set.
Biological Functiona Numbers of genes Gene Symbol
Actin cytoskeleton 12 ACTA2, ARHGAP15, ARHGEF6, CALD1, DOCK10, DOCK2, MARCKS, PALLD, PDLIM3, PDPN, SAMSN1, TPM1
Adhesion molecules 7 CD84, CDH11, EMP3, EPB41L3, ITGA4, PECAM1, TGFBI
ECM components 13 COL10A1, COL1A1, COL5A1, COL5A2, CRISPLD2, DCN, ECM2, FBN1, FN1, IFFO1, MXRA8, OLFML2B, OLFML3
Immune response 26
VSIG4, AIF1, ALOX5AP, C1QA, C1QB, CD14, CD53, CD93, COLEC12, 
CSF1R, CXCL12, CYBB, FCGR2B, FCGR3B, GIMAP6, HCK, IL10RA, 
LAIR1, LAT2, LCP2, MSR1, PTGER4, PTGIS, SH2B3, SIRPA, TLR7
Membrane receptors 13 AXL, EDNRA, EVI2A, EVI2B, FZD1, GPR65, HEG1, LAPTM5, MS4A4A, MS4A6A, PLXDC1, PLXNC1, TGFR2
Membrane trafficking 8 ATP6V1B2, ATP8B4, COPZ2, DAB2, MARCH1, PTPRC, PTRF, RAB31
Proteases 10 ADAM 12, CTSK, FAP, MMP19, MMP2, PCOLCE, PLAU, RECK, SERPINF1, TIMP3
Secreted molecules 5 ANGPTL2, FSTL1, HEPH, SFRP4, TGFB1
Transcription factors 11 AEBP1, FLI1, MAF, MAFB, MEF2C, MNDA, SNAI2, TGFB1/1, ZCCHC24, ZEB1, ZEB2
Others 16 CSGALNACT2, ENTPD1, GLIPR1, GLT8D2, LHFP, LHFPL2, MFSD1, NPL, PKD2, PLEK, PMP22, QKI, RGS4, RNASE6, SPATS2L, TM6SF1
aGenes are grouped according to their function. Genes included in the Axl-driven signature are in bold.
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Figure 6: A. Identification of an Axl–driven signature in serous HGEOCs. A. Evaluation of the expression changes of the genes 
included in the Axl-associated gene set in each of the HGEOC subtypes according to the TCGA data set [5]. A total of 114 out of the 121 
genes identified were plotted, due to differences in the gene symbols. Only the genes reported by Verhaak et al. [5] in the Supplementary 
Table 8A are plotted. The bars corresponding to Axl are reported in red. B. Graphical representation of the network identified by IPA. The 
top five networks, reported in Supplementary Table 5B, were identified by loading the genes reported in bold in Table 1. The Axl-correlated 
genes included in the network are highlighted in red.
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Axl-driven signature of 62 genes. Seventy percent of the 
ECM molecules and 100% of the secreted molecules were 
retained by applying this cut-off, whereas 50% or less of 
the molecules belonging to other categories, including 
to the immune response, were retained. IPA analysis 
performed on this gene list identified five top networks, 
of which the highest score was observed with ‘Tissue 
Morphology, Cell Morphology, Cellular Assembly and 
Organization’ (Fig. 6B). Besides the molecules of the Axl-
driven signature (reported in red in Fig. 6B), this network 
also included the ECM component ‘laminin’, and also 
‘integrin alpha V beta 3′, whose functionality is necessary 
for Gas6/Axl activation (see Fig. 2D). Overall, these 
findings further support the in vitro data presented above.
Axl-driven signature identifies the HGEOC 
patients with poor overall survival
To investigate the clinical relevance of this 
newly identified Axl-driven signature, we analyzed the 
correlation of AXL-driven signature expression with 
overall survival (OS) in data sets I and II by comparing 
the survival rates in patient groups with a ‘high’ and ‘low’ 
expression of the metagene consisting of the Axl-driven 
signature. In each of the two data sets analyzed, the patient 
group with a ‘high’ expression of the metagene had poor 
OS (log-rank p values of 0.0028 and 0.0059, respectively, 
Fig. 7). For data set I the adjusted hazard ratio (HR) was 
1.983 (95% confidence interval (CI) = 1.265–3.108), and 
for data set II, the HR was 1.666 [95% CI = 1.158–2.396]. 
Furthermore, HGEOC patients of data set I with ‘high’ 
metagene expression relapsed earlier than those with ‘low’ 
metagene expression (Supplementary Fig. 7).
Overall, our data establish for the first time a 
crosstalk between the Axl and ECM/integrin/p130Cas 
signaling pathways and identify an Axl-driven gene 
signature that could possibly be useful for the identification 
of HGEOC patients with poor outcome.
DISCUSSION
In this report, we unravel a novel signaling cascade 
induced upon Gas6 stimulation of HGEOC cells, whereby 
the Gas6/Axl axis, through a crosstalk with the integrin 
adaptor p130Cas, induces the invasion in Matrigel of 
ovarian cancer spheroids from cell lines and HGEOC 
patient-derived cells. In in vivo validation, represented by 
HGEOC samples, the Gas6 concentration was found to be 
elevated in HGEOC ascites, and Axl and p130Cas were 
co-expressed in type II HGEOCs. Clinically, we identified 
an Axl-driven molecular signature, whose predicted 
biological function basically recapitulated the signaling 
observed in vitro, and we were thus able to identify the 
HGEOCs with the poorest outcome.
In the last few years, Axl has been extensively 
studied and is described as a determinant of metastasis 
formation and progression for various types of solid 
tumors, including EOCs (for review see [10, 15]). 
However, this is the first report that deeply dissects the 
cellular and molecular events occurring in the EOC cells 
upon Axl activation due to Gas6 stimulation. The novel 
finding that the Gas6/Axl signaling cascade cooperates 
with the integrin pathway through p130Cas for the 
adhesion and invasion of EOC cells suggests that the 
process of EOC dissemination involves a plethora of 
different stimuli inducing the activation of more than 
a single signaling pathway. In a model of renal cell 
carcinoma, Gas6/Axl signaling induces metastasis 
formation through a crosstalk with src kinase and RTK 
Met [23], indicating that the molecular requirements 
necessary for Axl activation may be tumor-specific. Under 
physiological conditions, the crosstalk between integrins 
and the Axl receptor has so far only been observed 
in endothelial cells, and in this model, Axl tyrosine 
phosphorylation was induced in a Gas6-independent 
fashion by the formation of a complex between Axl and 
the β3 integrin, leading to endothelial cells survival [24]. 
Accordingly, we found that the inhibition of the interaction 
between the β3 integrin and the ECM led to a decrease in 
Axl phosphorylation; however, in contrast with the results 
on endothelial cells, in HGEOCs, the activation of Axl 
was dependent on both Gas6 stimulation and β3 integrin 
engagement.
The convergence between Axl and integrins was 
mediated by the adaptor protein p130Cas. P130Cas is 
a scaffold protein that is involved in the process of cell 
adhesion and migration upon integrin engagements with 
the ECM [25]. Although no correlation was observed 
between Axl and BCAR1, the gene encoding p130Cas, a 
significant association was observed between the Axl and 
p130Cas proteins with type II HGEOCs. This discrepancy 
is probably due to the different stability of the p130Cas 
transcript compared to the protein. In line with these 
results, high p130Cas expression was previously found in 
EOC and was associated with the advanced tumor stage, 
and hence decreased progression-free survival or overall 
survival [26]. Furthermore, p130Cas silencing in EOC 
cells induces an in vivo alteration of the apoptosome and 
increases cell death upon etoposide treatment. Moreover, 
the role of p130Cas in regulating tumor cell invasion 
through the release of matrix metalloproteinases such as 
MMP-9 has also been reported [27]. In colon cancer, the 
increased expression and activity of Src tyrosine kinase 
has been associated with persistent activation of the 
p130Cas/JNK pathways, the induction of MMP-2 and 
MMP-9, and invasion/survival in an α1-integrin-dependent 
fashion [28]. In several cancer cell lines, the association of 
the FAK–p130Cas complex to the focal adhesion sites has 
been described as being required for MMP-induced matrix 
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degradation and cell invasion [29]. In EOC, Axl activation 
has been linked with cell invasion through the induction of 
MMP-1 and MMP-9 [11]. Accordingly, we show here that 
the MMP-2 gene is included in Axl-associated signature, 
suggesting that the final consequence of the Axl and 
p130Cas crosstalk is the production of MMPs, which in 
turn leads to the invasion of EOC cells.
We demonstrated that during the process of cell 
invasion, the interaction between EOC cells and the ECM 
activates Gas6/Axl signaling cascade which in turn triggers 
the invasion process through the rac activation and actin 
remodeling. Very recently, a rac1/Pak1/p38/MMP-2 axis 
has been found to contribute to angiogenesis and the 
invasion of EOCs [30]. In breast cancer cells, Gas6/Axl 
signaling also leads to rac activation and invasion through 
the scaffold protein Elmo and the RHO-GTPase activator 
DOCK1 [31]. Our computational analysis highlighted 
DOCK10 within Axl-co-regulated genes, further 
indicating the importance of the actin remodeling for 
the Axl-expressing HGEOCs. The association between 
Axl activation and cytoskeleton organization was also 
supported by IPA analysis on the Axl-driven signature of 
62 genes, in which the identified network with the highest 
score was indeed associated with cell morphology. For all 
these reasons, investigations are ongoing to clarify the role 
of the DOCK activators and actin binding proteins during 
EOC progression.
The process of HGEOC peritoneal dissemination 
requires the re-attachment of EOC MCAs to the 
peritoneum or omentum, thus generating secondary 
lesions; this mechanism has been called mesothelial cell 
clearance [32]. Recently, a mesenchymal reprogramming 
of HGEOC MCAs was observed during mesothelial 
clearance [33]. In this report, Axl was one of the proteins 
whose expression increased in HGEOC cells competent 
for the mesothelial cell clearance. The requirement of 
adhesion to ECM for maximal Axl activation shown here 
is in accord with the notion that Axl could be a determinant 
of mesothelial cell clearance. The presence of Gas6 in 
HGEOC ascites and in the conditioned media of several 
EOC cell lines suggests that Gas6, released from the EOCs 
MCAs or by the cells of the immune system, acts like a 
fuel to favor tumor invasion and the establishment of 
secondary lesions.
Global gene expression analyses from the three 
data sets used in the present study help us identify novel 
molecular subtypes of HGEOCs based on their peculiar 
molecular signature and associated distinct biology 
[4, 5, 8]. Our data showed that the transcripts of Axl and 
that of co-regulated genes are increased in the subtype 
called ‘stroma’ by Tothill et al. [4], ‘mesenchymal’ by 
Verhaak et al. [5], and ‘mesenchymal-like’ by Konecny 
et al. [8]. Besides the denomination, this subtype is 
characterized by increase of the transcripts of genes 
encoding for EMT and ECM molecules, and in all the 
studies, it displays a significant shorter overall survival. In 
addition, bioinformatics tools indicated TGFB1 to be an 
up-stream regulator of the Axl-associated signature, which 
includes several ECM proteins. A collagen-remodeling 
gene signature, regulated by TGF-β signaling, has also 
been found to be associated with metastasis formation 
and a poor prognosis [34]. Although this signature only 
included two genes, COL5A1 and TIMP3, which are 
common to the Axl-associated signature, together these 
data indicate that the most aggressive HGEOCs display 
peculiar extracellular components whose expression 
should be taken into account when alternative therapeutic 
approaches are considered for these patients.
Interestingly, the genes increased in the above-
mentioned HGEOC subgroups were decreased in the 
HGEOC subtype named ‘proliferative’ [4, 21] and 
‘proliferative-like’ [8], which are characterized by a 
slightly better outcome. These data clearly indicate that 
the biology of HGEOCs included in the mesenchymal 
Figure 7: Axl-driven signature identifies the HGEOC patients with poor overall survival. Kaplan-Meyer curves, log-rank 
p values and HR are used to compare OS between HGEOC patients with ‘high’ (red lines) and ‘low’ (green lines) expression intensities 
of the metagene consisting of the Axl-driven signature. The tables below each curve reports the median survival of each group of patients.
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subgroup is different from the biology of HGEOCs 
belonging to the proliferative subtype. We can hypothesize 
that the signaling pathway identified in this study is one 
of the pathways activated in the ‘mesenchymal’ HGEOC 
subtype. Our experimental data represent a step forward 
in gaining an understanding of the molecular mechanism 
associated with the progression of HGEOCs and suggest 
that the Gas6/Axl/p130Cas axis can be exploited as a 
therapeutic target in combination with chemotherapy to 
cure those patients whose tumors molecularly recapitulate 
the most aggressive EOC subtype, which will likely 
recur earlier with the formation of new metastases and 
uncontrolled dissemination.
HGEOC is a clinically separate and molecularly 
heterogeneous disease comprising subtypes with different 
response rates to conventional chemotherapy. The 
definition of a molecular signature for the identification 
of HGEOC patients, as well as for one of the pathways 
possibly activated in these HGEOCs, may help to provide 
a more effective and tailored therapeutic approach.
 MATERIALS AND METHODS
Antibodies and reagents
Abs against P-Axl(Y702) (rabbit), P-AKT(S473) 
(rabbit), anti-Mer (mouse), P-src (Y416), and 
anti-P-Tyrosine (P-Tyr-100) (mouse) were obtained 
from Cell Signaling Technology (New England BioLabs, 
Beverly, MA, USA); anti-Axl (goat), anti-FAK (rabbit), 
anti-Tyro-3 (goat), and anti-β1 and anti-p130Cas (mouse) 
from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA); anti-α-tubulin (mouse) from Thermo Scientific 
(Fremont, CA, USA); anti-β-actin (rabbit) from Sigma-
Aldrich (Saint Louis, MO, USA); anti-β3 from Abcam 
(Cambridge, UK); and anti-β4 from Millipore (Merck 
Millipore, Oxford, UK).
Alexa Fluor 488 phalloidin was obtained from 
Molecular Probes (Invitrogen, Carlsbad, CA, USA). 
Human recombinant Gas6 and Axl-Fc were from R&D 
systems, Inc. (Minneapolis, MN, USA), as was the 
ELISA for Gas6 dosage. FN was from Sigma-Aldrich. 
The Taqman Gene Expression Assays were from Applied 
Biosystems (Foster City, CA USA). Puromicine and 
Lipofectamine 2000 were from Invitrogen. R428, the 
Axl inhibitor, was from Rigel (South San Francisco, CA, 
USA); EHT1864, the Rac inhibitor, was from Tocris 
(Minneapolis, MN, USA).
Cell lines
The human ovarian cancer cell lines used in this 
study were: IGROV-1, kindly provided by Dr Bénard 
(Paris, France) [35]; SKOV3, from ATCC; OVCAR4 and 
OVCAR5, provided by Dr Camalier (NCI-NIH, USA); 
and NL3507, from Dr van den Berg-Bakker (Leiden, the 
Netherlands)[36]. They were maintained in RPMI 1640 
medium (Sigma-Aldrich) supplemented with 10% fetal 
calf serum (FCS) (Hyclone, Logan, UT, USA) and 1% 
L-glutamine at 37°C in a humidified atmosphere of 5% 
CO
2
 in air. OAW42 was provided by Dr A. Ullrich, (Max 
Planck Institute of Biochemistry, Martinsried, Germany) 
[37], and maintained in DMEM supplemented with 10% 
FCS and 1% L-glutamine in a humidified atmosphere 
of 5% CO
2
. Cells were genotyped at the Functional 
Genomic facility of our Institute, using a Stem Elite ID 
System (Promega, Madison, WI, USA), according to the 
manufacturer’s instructions and ATCC guidelines. Cells 
were routinely confirmed to be mycoplasma-free by 
Hoechst staining and by using a MycoAlert Mycoplasma 
Detection Kit (Lonza, Basel, Switzerland).
For the biochemical analysis, Gas6 stimulation was 
performed on starved cells in serum-free medium for 30 
min at a concentration of 500 ng/ml. Recombinant human 
Axl-Fc chimera was used at 2.5 μg/ml and added 1 hr 
before the addition of Gas6 or the serum-free medium.
Patients and samples
Twenty-two ascites from EOC patients, whose 
characteristics are reported elsewhere [20], were collected 
at the time of debulking surgery. The Institutional Review 
Board approved the use of archived material and ascites, 
as well as the clinical data. All the clinical specimens were 
accompanied by the informed consent from all patients 
to use the excess biological material for investigative 
purposes. The histological selection of patients was based 
on them being at an advanced stage at diagnosis and the 
presence of ascites at surgery. Samples of nonmalignant 
ascites were obtained from cirrhotic patients that had 
undergone therapeutic paracentesis and had been admitted 
to the Clinica Medica Ward of AOU Maggiore della 
Carita’ University Hospital at Novara, Italy. Patient-
derived 3D cultures were obtained by using MCAs from 
serous HGEOC ascites collected at the time of surgery.
The study group consisted of 72 cases of EOCs 
diagnosed between January 1, 2006 and December 31, 
2011 in “St. Spiridon” Emergency Clinical Hospital and 
“Cuza Vodă” Obstetrics and Gynecology Clinical Hospital 
from Iassy, Romania. The study was approved by the Ethics 
Committee of the “Grigore T. Popa” University of Medicine 
and Pharmacy, Iassy, based on the patients’ informed 
written consent for the usage of the biologic material. 
The TMA preparation and the immunohistochemical 
investigation were performed at Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan, Italy.
RNA extraction and real-time RT–PCR analysis
Total RNA from ovarian cancer cell lines was 
extracted using a commercial kit (Amersham Bioscience-
GE Healthcare, Piscataway, NJ, USA). Frozen tissues 
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were homogenized using a bead-mill device (TissueLyser, 
QIAGEN Sciences, Germantown, MD, USA), then 
total RNA was purified with the NucleoSpin miRNA 
(Macherey-Nagel, Duren, Germany) according to the 
manufacturer’s instructions. For the formalin-fixed, 
paraffin-embedded (FFPE) HGEOC samples, RNA 
was isolated with the miRNeasy FFPE Kit (QIAGEN 
Sciences), following the manufacturer’s instructions. 
A High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) was used to perform the reverse 
transcription reaction according to the manufacturer’s 
instructions. Real-time RT-PCR was performed using the 
7900 system (Applied Biosystems) TaqMan Fast Universal 
PCR Master Mix (Applied Biosystems), according to the 
manufacturer’s instructions. TaqMan Gene expression 
assays (Applied Biosystems) were used and are listed in 
the Supplementary Table 6.
Western blotting and IP
Cells were washed with ice-cold PBS containing 
sodium ortovanadate (0.1 mM) and lysed with 
NuPAGE® LDS Sample Buffer (1x) (Invitrogen) plus 
β-Mercapto. Proteins were separated on precast 4–12% 
SDS-polyacrylamide gels (Invitrogen). A western blot 
was performed as described [20] and analyzed using a 
ChemiDoc XRS system and the Quantity One® software 
from Biorad (Hercules, CA, USA).
IP was performed, essentially as described [38]. 
Briefly, cells were lysed in cold lysis buffer (150 mM 
NaCl, 50 mM Tris-HCl, pH 7.4, 0.25% NaDoc, 1 mM 
EDTA pH 8, 1 mM Na
3
VO
4
, 1% PMSF, 1% Np-40, and 
protease inhibitors) for 30 min on ice. The cellular debris 
and nuclei were removed by centrifugation at 13000 rpm 
for 30 min at 4°C. Normal rabbit or mouse sera were 
used as the negative control. Primary ab was bound to 
beads conjugated with goat anti-mouse or anti-rabbit ab 
(Dynabeads; Dynal ASA, Oslo, Norway) and incubated 
with cell extracts overnight at 4°C with rotation. Beads 
were washed once with cold lysis buffer, twice with PBS 
plus BSA, and with protease inhibitors (10 min/wash). 
Immunoprecitated proteins were separated by SDS- mini-
gels (Invitrogen) under reducing conditions.
3D cultures and the invasion assay
In a 3D Algimatrix™ culture system 96-well plate 
(Gibco, Carlsbad, CA, USA), cells with a density of 
1 × 103 were incorporated into the 3D alginate scaffold 
in 100 μL of media, according to the manufacturer’s 
protocol. After 20 min, another 150 μL of media was 
added and the cells were grown in the incubator at 37°C 
with 5% CO
2
. The media was changed every 5 days. 
Gas6 treatment was started at 12 days post cell seeding. 
In some experiments, the spheres were dissolved from 
the Algimatrix scaffold according to the manufacturer’s 
protocol and seeded into Matrigel in a serum-free medium 
or in the presence of Gas6 500 ng/ml. Morphological 
changes in the spheres shapes were monitored for up to 
48 hr using an inverted microscope with a 20X or 40X 
0.75 NA PlanFluor objective (Nikon, Tokyo, Japan). The 
images were acquired with ACT-1 software (Nikon).
For the Matrigel 3D culture, cells (1 × 103) were 
suspended in a medium of growth factor-reduced 
Matrigel (BD Biosciences, Bedford, MA, USA) and then 
seeded directly onto uncoated 48-well culture plates. 
The plates were first incubated for 30 min at 37°C and 
then the complete medium was added. Upon formation 
of the spheres (after about a week), an invasion assay 
was performed on cells starved overnight. Starved cells 
were stimulated with Gas6 (500 ng/ml). For the HGEOC 
patient-derived 3D culture, cells were re-suspended in 
serum-free medium alone or in the presence of 500 ng/ml 
Gas6 and plated onto growth factor-reduced Matrigel 
in 48-well plates. Drug pre-treatment for the invasion 
assay was performed upon formation of the spheres. 
Morphological changes of the spheres were monitored for 
up to 48 hr using an inverted microscope with a 20X or 
40X 0.75 NA PlanFluor objective (Nikon). The images 
were acquired with ACT-1 software (Nikon). A medium 
number of 30 spheres was analyzed for each experiment.
Live imaging
Serum-starved SKOV3 cells, transfected with 
siRNA against p130Cas or with a control siRNA for 48 hr, 
were left in suspension for 1 hr before being seeded on 
FN (20 ug/ml) pre-coated 8-well glass chamber slides 
(Nalge Nunc International, NY, USA), and were then 
stimulated or not with Gas6 500 ng/ml. Cell-adhesion 
on FN was monitored for up to 1 hr by live-imaging 
using a 20X 0.5 NA Plan-Fluor DIC dry objective. The 
microscope (NIKON TE300 ECLIPSE) was equipped 
with an incubation chamber, which provided a humidified 
atmosphere at 37°C with 5% CO
2
. Cells were counted 
based on five field digital images taken randomly. The 
average number of cells and SD were calculated based on 
triplicate experiments.
IF
Cells seeded on 8-well glass chamber slides pre-
coated with FN 20 μg/ml (Nalge Nunc International) 
were grown for 24 hr, serum starved and then stimulated 
or not with Gas6 500 ng/ml. Before immunostaining, the 
cells were fixed with 2% paraformaldehyde for 20 min 
and permeabilized for 10 min in PBS/Tween 0.1%. The 
samples were then blocked for 30 min with PBS/1% 
BSA. Samples were mounted with Prolong Gold Antifade 
reagent with DAPI (Invitrogen) and analyzed using an 
Eclipse TE2000-S microscope with a 40X PlanFluor 
objective (Nikon). Images were acquired with ACT-1 
software (Nikon). All the procedures were carried out at 
room temperature.
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Flow cytometry
Cells were permeabilized in 70% cold ethanol for 
30 min on ice and stained by sequential incubation with 
primary and secondary mAbs. Cells were analyzed for 
antigen expression by a FACSCalibur cytofluorimeter 
(BD Biosciences). The percentage of positive cells and 
the median fluorescence intensity after background 
subtraction were recorded.
siRNA and transfection
Cells were transfected with 40 nmol/ml of small-
interfering RNA (siRNA) duplex specific for p130Cas 
(Smart Pool, Thermo Scientific, Dharmacon, Inc. Chicago, 
IL, USA) or control siRNA (Quiagen). Transfection 
was performed using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. Whole cell 
lysates were prepared 48 hr after transfection. In one of the 
experiments, serum-starved p130Cas-silenced or control-
transfected SKOV3 cells were left in suspension for 1 hr 
before being seeded on FN (20 ug/ml) and stimulated or 
not with Gas6 500 ng/ml for 30 min, and the total cell 
lysates were analyzed by western blotting.
Stable p130Cas silencing
The pLKO.1 lentiviral vector carrying a shRNA 
directed to human p130Cas (p130Cas shRNA) was 
selected in the pLKO.1 target gene shRNA set (clone ID 
TRCN0000115985), purchased from Open Biosystem 
(Huntsville, AL, USA). The pLKO.1 scramble shRNA 
vector (Addgene, Cambridge, MA, USA) was used as 
the negative control. Lentiviral particles were generated 
and concentrated by ultracentrifugation (50,000 g, 2 hr). 
SKOV3 cells were infected with the lentiviral p130Cas-
shRNA (sh-p130Cas) and scramble-shRNA (Mock). 
Puromycin (Sigma-Aldrich) (0.8 lg/ml) was added 24 hr 
after infection with the PLKO.1 vectors.
Gas6 and soluble Axl assay
Gas6 was measured with a sandwich ELISA 
modified from that already published [13]. Briefly, a 
96-well plate (ImmunoPlates MaxiSorp F96, NUNC, 
Hereford, UK) was coated overnight with anti-Gas6 
primary antibody (goat polyclonal affinity purified 
IgG, R&D Systems). The antigen was detected by a 
secondary biotin-conjugated antibody (Biotinylated anti 
human Gas6 antibody, R&D Systems), a streptavidin-
peroxidase conjugate (Sigma-Aldrich), and TMB 
(3,3′,5,5′-tetramethylbenzidine, Sigma-Aldrich). The 
reaction was blocked with sulphuric acid 1.8 M and 
the absorbance detected at 450 nm with the reference 
wavelength set at 570 nm. The optical density was 
fitted against the nominal concentration by applying a 
four-parameter logistic regression to the calibration curve 
prepared in BSA (bovine serum albumin, further purified 
fraction V, ≥98%, Sigma-Aldrich).
A soluble Axl assay was performed with a 
commercial ELISA kit (DuoSet IC R&D Systems), 
following the manufacturer’s instructions.
IHC
Paraffin-embedded EOC tumors were analyzed with 
anti-Axl and anti-p130Cas Abs. IHC was performed after 
deparaffinization, as described [38]. The primary goat anti-
human Axl Ab was diluted 1:25 and the primary mouse 
anti-human p130Cas Ab was diluted 1:400. Incubation 
with each of the primary antibodies was performed 
overnight at 4°C, then the slides were incubated for 30 min 
at room temperature with the secondary biotinylated 
antibodies diluted 1:200. The slides were washed with 
PBS, and the peroxidase activity was revealed by 
incubating sections in DAB (3–3′diaminobenzidine) 
(DAKO, Denmark) for 5 min. After washing with water, 
sections were counterstained with Gill’s hematoxylin 
solution for 5 sec.
Computational analysis of the gene 
expression data
Gene expression data were downloaded as raw 
signals from GEO (GSE9891 [4]) and from the TCGA 
repository (https://tcga-data.nci.nih.gov/tcga) for data set 
I and II, respectively, or as a processed matrix from GEO 
for data set III (GSE53963 [8]). Raw gene expression data 
were RMA-normalized through the Expression Console 
software (Affymetrix, Santa Clara, CA, USA). Data set I 
was filtered for the serous histotype, for consistency with 
the two other data sets. The AXL probe 202686_s_at 
was selected for the two data sets processed through the 
Affymetrix platform (data sets I and II), while the probe 
A_23_P208389 was selected for the Agilent data set (data 
set III). Among each data set, the selected AXL probe was 
analyzed for Pearson’s correlation against all the other 
probes by using the cor, cor.test, and p.adjust bioconductor 
functions in the R programming language (version 3.0.2, 
http://www.r-project.org), in order to calculate the Pearson’s 
correlation coefficients (r), the p value, and the Benjamini 
and Hochberg FDR, respectively. The AXL-correlated 
probes were filtered for r ≥ 0.4 and FDR ≤ 4.53E-08. The 
Axl-associated gene set comprised the 121 genes commonly 
correlated in all of the three data sets. This Axl-associated 
gene set was then screened in the four HGEOC subtypes, 
as described by Verhaak et al. [5] in the Supplementary 
Table 8A (Fig. 6A), and only the genes up-regulated in the 
mesenchymal subtype with an F score higher than 1.6 were 
conserved. The resulting reduced list of 62 genes was thus 
considered the Axl-driven signature. The F score for a given 
gene is defined by Verhaak et al. [5] as the measure used 
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by the significance analysis of a microarray to indicate the 
differences in gene expression between two groups.
The Axl-associated gene set of 121 genes and the 
Axl-driven signature were further analyzed by Ingenuity 
Pathway Analysis (IPA), and a core biological pathway 
analysis was performed to identify the molecular networks 
and upstream regulators.
OS analysis of the microarray data
We performed the survival analysis using a single 
metagene from the Axl-driven signature of the 62 genes. 
We calculated a single metagene value for each data set 
by performing the mean of the expression values of the 
genes in each patient. Finally, in each data set, we divided 
patients with a metagene value higher than the second 
tertile from all the others and performed the survival 
analysis. The ‘risk index’ of the 62 genes was calculated 
from a linear combination of the gene expression values 
and their estimated multivariable Cox proportional hazard 
regression coefficients. The median risk index was used to 
define the two patient groups: one group was characterized 
by a high expression of the 10 genes and the other by a 
low expression of the 10 genes. The Kaplan–Meier 
method was used to estimate OS and the log-rank test was 
applied to compare OS across the groups. All the analyses 
were performed using R packages.
Statistical analyses
GraphPad Prism software (GraphPad Software, 
San Diego, CA, USA) was used to analyze all the data. 
Differences between the mean values were analyzed by 
Student’s t test and a two-way ANOVA. The correlation 
of Axl and p130Cas expressions in IHC was evaluated 
by Fisher’s exact test. P values < 0.05 were considered 
significant.
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